Cancer name Colon Cancer
Cancer Type COCA
Immunotherapy type Adoptive Cell Therapy
Treatment γδT cells
Drugstatus NA
Drugbank ID NA
Checkpoints NA
Signature Type Cell
Signature γδT cells
Official Symbol T cell
Mode of action CE_D_UP
Description for ‘mode of action’:the ‘mode of action’ for signature is composed of three parts: A_B_C. A describes the level at which the corresponding signature changes, it may contain the following values: TRAN(translation), PROT(protein), CE(cell), METH(methylation), AC(acetylation), PHOS(phosphorylation), MU(mutation), SNP(single nucleotide polymorphism), GLYC(glycosylation) and PATH(pathway). B describes the corresponding signature in which cancer immunotherapy condition group has changed, it may contain the following values: R (immunotherapy response group), NR(immunotherapy non-response group), D (Immunotherapy group), ND (No immunotherapy group). C describes the change detail (specific direction) of the corresponding signature, it may contain the following values: UP (High gene/protein expression or increased cellular abundance or enhanced epigenetic modification), DN (Low gene/protein expression or reduced cellular abundance or attenuated epigenetic modifications), LOSS (deletion mutation), GAIN (gain mutation),Other. For example, the search/browse detail result for CD274 was “PROT_R_UP”, it can be interpreted that the protein level of CD274 was upregulated in immunotherapy response individuals.
Experimental cell lines
Description We found that the low concentrations of TWS119 (0.5–2.0μM) obviously upregulated the percentage ofγδT cells and increased the total number of live cells andγδT cells in a dose-dependent manner. The expression of CCR5, CD62L and CD45RA in γδT cells was assessed by flow cytometry. We found that TWS119 upregulated theexpression of CCR5 and CD62L in a dose-dependent manner but did notalter the expression level of CD45RA inγδT cells.
PMID 29104081
Title Wnt pathway activator TWS119 enhances the proliferation and cytolytic activity of human γδT cells against colon cancer